DF
FATE icon

Dunhill Financial’s Fate Therapeutics FATE Stock Holding History

Dunhill Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.59K Hold
3,180
– – ﹤0.01% 610
2026
Q1 		$3.82K Hold
3,180
– – ﹤0.01% 676
2025
Q4 		$3.13K Hold
3,180
– – ﹤0.01% 672
2025
Q3 		$4.01K Hold
3,180
– – ﹤0.01% 587
2025
Q2 		$3.56K Hold
3,180
– – ﹤0.01% 590
2025
Q1 		$2.51K Hold
3,180
– – ﹤0.01% 697
2024
Q4 		$5.25K Hold
3,180
– – ﹤0.01% 529
2024
Q3 		$11.1K Hold
3,180
– – 0.01% 357
2024
Q2 		$10.4K Hold
3,180
– – 0.01% 280
2024
Q1 		$23.3K Hold
3,180
– – 0.02% 162
2023
Q4 		$11.9K Buy
+3,180
New +$7.51K 0.01% 185

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dunhill Financial's FATE Position: Q2 2026 in Review

Dunhill Financial held its Fate Therapeutics (FATE) position steady in Q2 2026 at 3,180 shares worth $8.59K. The position accounts for ﹤0.01% of the portfolio, ranked #610.

Dunhill Financial first reported a position in FATE in Q4 2023 and has held it in 11 quarters since. The position peaked at $23.3K in Q1 2024. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Dunhill Financial held 3,180 shares of Fate Therapeutics worth $8.59K as of Q2 2026.
  • Dunhill Financial left its Fate Therapeutics share count unchanged in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #610 holding.
  • Dunhill Financial first reported a position in Fate Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Dunhill Financial's Fate Therapeutics position peaked at $23.3K in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.